ArticleEndocrine2022
Cardiometabolic profile of young women with hypoprolactinemia.
Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- How to Define Success in Prolactinoma Treatment-A Systematic Review and Theoretical Framework.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Quality of life in Prolactinoma: A systematic review.Pituitary · 2024Pooled it
- Cardiometabolic effects of sequential prolactin states in dopamine agonist-treated prolactinoma patients: a retrospective longitudinal study.Pituitary · 2026Observational
- The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study.Pituitary · 2026Article
- Association between Prolactinoma and Incident Type 2 Diabetes Mellitus: Evidence from a Korean Nationwide Cohort.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study.Pituitary · 2025Article
- The impact of hypoprolactinemia on cardiometabolic effects of metformin in young women: a pilot prospective cohort study.Journal of endocrinological investigation · 2025Article
- Mildly elevated serum prolactin level may be a protective factor for preventing thickening of the carotid intima-media in patients with type 2 diabetes mellitus.Endocrine connections · 2025Article
- Article
- Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus : "Absence of proof is not the proof of absence".Reviews in endocrine & metabolic disorders · 2024Review
- Isolated hypoprolactinemia: The rarest of the rare?Reviews in endocrine & metabolic disorders · 2024Review
- Drug induced hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024Review
- The molecular basis of hypoprolactinaemia.Reviews in endocrine & metabolic disorders · 2024Review
- Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study.Reviews in endocrine & metabolic disorders · 2024Review
- Cardiometabolic effects of hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024Review
- Could low prolactin levels after radiotherapy predict the onset of hypopituitarism?Reviews in endocrine & metabolic disorders · 2024Review
- What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review.Reviews in endocrine & metabolic disorders · 2024Review
- Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study.Biomolecules · 2024Article
- Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUnlike hyperprolactinemia, clinical significance of prolactin deficiency remains poorly understood. The aim of this study was to assess the cardiometabolic profile of patients with low prolactin levels.
methodsThe study population consisted of three groups of young women. Two groups were chronically treated with cabergoline but differed in prolactin levels, which were either abnormally low (group A; n = 16) or within the reference range (group B, n = 23). Group C, serving as a control group, included 28 drug-naïve women with normal prolactin levels. The dose of cabergoline in group A was then tapered down. Glucose homeostasis markers, plasma lipids and circulating levels of hormones, uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine, as well as the carotid intima-media thickness were assessed at baseline and 6 months later.
resultsCompared with subjects with normal prolactin levels, women with hypoprolactinemia had higher levels of 2-h postchallenge glucose, glycated hemoglobin, triglycerides, uric acid, hsCRP and fibrinogen, lower values of HDL-cholesterol, total testosterone and free androgen index, as well as reduced insulin sensitivity. No differences in these variables were observed between groups B and C. Apart from prolactin normalization, cabergoline dose reduction reversed all laboratory disturbances reported in group A.
conclusionThe obtained results suggest that hypoprolactinemia in women of reproductive age may increase cardiometabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.